ESMO 2019 Conference Review - focus on Breast Cancer, reviewed by Dr. Hilary Martin

In this review:

Clinical outcomes in patients with RS 26-100 in TAILORx
Prognostic value of TILs in earlystage TNBC without chemotherapy
KEYNOTE-522: neoadjuvant & adjuvant pembrolizumab in early TNBC
Veliparib + carboplatin/paclitaxel in HER2 negative advanced BRCA associated BC
Performance of PD-L1 IHC assays in locally advanced/metastatic TNBC
Trilaciclib + gemcitabine/carboplatin in patients with mTNBC
KEYNOTE-119: pembrolizumab vs single-agent chemotherapy for mTNBC
Trastuzumab emtansine + atezolizumab vs trastuzumab emtansine + placebo in advanced HER2+ BC
Abemaciclib/trastuzumab ± fulvestrant vs trastuzumab + chemotherapy in HR+, HER2+ advanced BC
KATHERINE trial: peripheral neuropathy, thrombocytopenia & CNS recurrence

Please login below to download this issue (PDF)